Compare Organon & Co. Common Stock (OGN) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs VanEck Vietnam ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while VanEck Vietnam ETF trades at $16.38 (market cap $465.30M). The key difference: Organon & Co. Common Stock is far larger — about 7.8× VanEck Vietnam ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and VanEck Vietnam ETF for 52 Days on average.
| OGN | VNM | |
|---|---|---|
Market Cap | $3.62B | $465.30M |
Volume | 2,892,999 | 633,123 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $19.80 |
52-Week Low | $5.70 | $16.34 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VNM stock trades at $16.53, down 0.3% with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while trading at fair valuation. Recent news highlights Vietnam's potential US trade deal progress, though the fund has underperformed despite country growth prospects.
Near-term outlook remains cautious due to technical weakness and sector headwinds. Long-term exposure to Vietnam's growth offers potential, but investors face volatility from interest rate sensitivity and concentrated sector risks. The bearish technical setup suggests continued pressure on current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
